Evaluating pediatric ureteropelvic junction obstruction: Dynamic magnetic resonance urography vs renal scintigraphy 99m-technetium mercaptoacetyltriglycine

Table 3 Characteristics of the patients enrolled in the study (n = 40), n (%)

	Scintigraphy MAG-3 + dMRU, n = 40	Group A < 10% discrepancy, n = 31	Group B > 10% discrepancy, n = 9	P valuea
Sex				0.697
M	28 (70)	21 (75)	7 (25)
F	12 (30)	10 (83)	2 (17)
Age at surgery, months	30 (14-127)	37 (14-134)	27 (13-76)	0.641
Diagnosis				0.0897
Prenatal	31 (77.5)	22 (71)	9 (29)
Postnatal	9 (22.5)	9 (29)	0
Associated anomalies				0.999
Duplication of urinary system	0	0	0
Ureterocele	0	0	0
Single kidney	1 (2.5)	1 (3)	0
Horseshoe kidney	0	0	0
Vesicoureteral reflux	3 (7.5)	1 (3)	2 (22)	0.999
Pyelonephritis	7 (17.5)	6 (19)	1 (11)	0.999
Urinary stones	1 (2.5)	1 (3)	0	0.999
Follow-up, months	12 (5-20)	10 (3-16)	19 (10-26)	0.05

^aP value: Potential risk factors for a discrepancy in renal function between group A and group B (P < 0.05 was considered statistically significant).

Values are shown as n (%) or median (interquartile range), as appropriate. Group A: Discrepancy in renal function between scintigraphy and dynamic contrast-enhanced magnetic resonance urography (dMRU) is < 10%. Group B: Discrepancy in renal function between scintigraphy and dMRU is > 10%. dMRU: Dynamic contrast-enhanced magnetic resonance urography; MAG-3: 99m-technetium mercaptoacetyltriglycine; F: Female; M: Male.